How should low ferritin with high transferrin saturation be evaluated and managed?

Low Ferritin with High Transferrin Saturation: Evaluation and Management

Low ferritin with high transferrin saturation is not a typical pattern and requires immediate investigation to exclude iron deficiency anemia, functional iron deficiency, or early hemochromatosis with recent blood loss or other confounding factors.

Initial Diagnostic Approach

This paradoxical pattern demands careful evaluation because:

• Low ferritin typically indicates depleted iron stores and should correlate with low transferrin saturation in straightforward iron deficiency
• High transferrin saturation (>45% in women, >50% in men) suggests increased circulating iron and is the hallmark of hemochromatosis 1
• The combination suggests either:
  1. True iron deficiency with a confounding factor affecting transferrin saturation measurement
  2. Functional iron deficiency where inflammation or other factors alter ferritin interpretation 2
  3. Early or treated hemochromatosis with concurrent iron depletion

Specific Evaluation Steps

1. Verify the Laboratory Results

• Repeat fasting iron studies including serum iron, transferrin or TIBC, ferritin, and calculate transferrin saturation 1
• Ensure the patient was fasting, as non-fasting samples can falsely elevate transferrin saturation
• Check for hemolysis in the sample, which can spuriously elevate serum iron

2. Assess for Iron Deficiency Anemia

• Hemoglobin and complete blood count: Look for microcytic anemia (MCV <80 fL) 3
• In the absence of inflammation, ferritin <45 ng/mL is diagnostic of iron deficiency 3
• With inflammation present, ferritin <100 ng/mL indicates iron deficiency 3
• Consider measuring soluble transferrin receptor (sTfR) and the sTfR/log-ferritin index to distinguish true iron deficiency from anemia of inflammation, though sTfR itself is influenced by inflammation 4

3. Evaluate for Hemochromatosis

Despite low ferritin, high transferrin saturation warrants hemochromatosis screening:

• HFE genotyping for p.C282Y mutation should be performed in individuals of European origin with transferrin saturation >45% in females or >50% in males, even if ferritin is low 1
• This is critical because:
  • Transferrin saturation is the earliest biochemical abnormality in hemochromatosis
  • Ferritin may be temporarily low due to recent blood loss, menstruation, or dietary restriction
  • Patients with hemochromatosis can develop concurrent iron deficiency from bleeding

4. Investigate Underlying Causes

For women of reproductive age:

• Heavy menstrual bleeding (most common cause) 3
• Uterine adenomyosis or fibroids 2
• In adenomyosis specifically, the correlation between hemoglobin and transferrin saturation is weak (r=0.21), and functional iron deficiency (TSAT <20% with ferritin ≥20 ng/mL) is common 2

For all patients:

• Gastrointestinal blood loss accounts for 94% of cases in men and postmenopausal women 3
• Bidirectional endoscopy is mandatory in men and postmenopausal women 3
• Test for H. pylori and celiac disease (both common causes) 3
• Assess medication use: SGLT2 inhibitors and possibly GLP-1 receptor agonists alter ferritin interpretation 4

5. Check for Inflammation

• C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) to identify inflammatory states that may suppress ferritin or alter iron metabolism 4
• In severe inflammation, ferritin >10,000 μg/L suggests hemophagocytic lymphohistiocytosis (HLH), though this is not relevant to your low-ferritin scenario 4

Management Algorithm

If Iron Deficiency is Confirmed:

Oral iron replacement (first-line):

• Every-other-day dosing improves absorption compared to daily dosing 3
• Evaluate response in 2-4 weeks with repeat hemoglobin and iron studies 3
• Approximately 50% of patients have decreased adherence due to gastrointestinal adverse effects 3

Intravenous iron (specific indications):

• Intolerance to oral iron
• Inadequate response to oral iron after 2-4 weeks
• Heart failure patients (to increase exercise capacity) 3
• Hypersensitivity to newer IV iron formulations is rare (<1%) 3

If Hemochromatosis is Diagnosed:

Even with low ferritin, if p.C282Y homozygosity is confirmed:

• Monitor closely as ferritin will rise once the cause of iron loss is addressed
• Avoid iron supplementation 1
• Restrict alcohol intake during any iron depletion phase 1
• Limit red meat consumption 1
• Avoid vitamin C supplementation (enhances iron absorption) 1
• Once ferritin rises, initiate phlebotomy therapy targeting ferritin 50-100 μg/L during maintenance 1

Critical Pitfalls to Avoid

1. Do not dismiss high transferrin saturation simply because ferritin is low – this may represent early hemochromatosis with concurrent blood loss
2. Do not supplement iron without investigating the cause of the low ferritin, especially in men and postmenopausal women where GI malignancy must be excluded 3
3. Do not rely on ferritin alone in patients with inflammation, adenomyosis, or metabolic conditions – transferrin saturation provides complementary information 2, 5
4. Document use of SGLT2 inhibitors or GLP-1 agonists as these medications alter ferritin interpretation 4
5. In hemochromatosis patients, transferrin saturation may remain elevated (>50%) even when ferritin is at target – this persistent elevation correlates with symptoms like fatigue and joint pain and reflects plasma non-transferrin-bound iron (NTBI) that drives tissue damage 5

Monitoring Considerations

The 2022 EASL guidelines on hemochromatosis emphasize that transferrin saturation should be monitored alongside ferritin, as TSAT >50% regardless of ferritin level is associated with general and joint symptoms in HFE-related hemochromatosis 1. Recent evidence from 2026 strongly advocates for including TSAT as a therapeutic target, not just ferritin, because TSAT above ~75% suggests harmful NTBI levels that drive organ damage 5.